Medicinal Psychedelics with MindBio Therapeutics

Andrew Clarke
  • 5.0 (1)
  • Business

This is the first of a series looking at the burgeoning Medicinal Psychedelics industry, of which MindBio Therapeutics is a leading player. Justin Hanka, co-founder and director of MindBio Therapeutics, talks about why, as an investment banker he got involved in medicinal psychedelics, and what excites him about the research.

Episodes

  1. 11/02/2021

    Medicinal Psychedelics - The Investment Buzz

    Medicinal Psychedelics are making quite a noise on the global investment markets, MindBio Therapeutics is one business in this space. In this video, Justin Hanka explains a little about why he got involved in MindBio and why there is an investment buzz around the industry.   MindBio Therapeutics is a clinical-stage drug development company that is pioneering psychedelic microdosing. With its first candidate drug LSD currently in Phase 1 clinical trials microdosing LSD in 80 healthy participants.    In a world-first clinical trial of its kind, participants are prescribed the microdoses to take home with them after receiving a battery of psychological and biometric baseline tests in the laboratory. Phase 2 clinical trials microdosing LSD have just been approved in late-stage cancer patients experiencing existential distress, anxiety and depression.    MindBio Therapeutics has a unique drug formulation strategy that will integrate with artificial intelligence and technology development for the enhanced safety, optimal dosing and monitoring of patients.   #mentalhealth #microdosing #mindbio #AlbertHofmann #LSD

    Medicinal Psychedelics - The Investment Buzz

  2. 10/07/2021

    Medicinal Psychedelics Episode 01

    In this episode we have a chat with Justin Hanka from MindBio Therapeutics on the research they are undertaking, and why he got involved.

  • 2 Episodes

About

This is the first of a series looking at the burgeoning Medicinal Psychedelics industry, of which MindBio Therapeutics is a leading player. Justin Hanka, co-founder and director of MindBio Therapeutics, talks about why, as an investment banker he got involved in medicinal psychedelics, and what excites him about the research.

Information